Clinical trials: Auto Immune Disorders
B-cell Acute Lymphoblastic Leukemia
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue.
- Trial name
- NCT05470777
- Testing
- CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Down Syndrome With and Without Auto Immune Abnormalities
Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome
The purpose of the study is to identify biological data linked to auto immune abnormalities associated with Down Syndrome.
- Trial name
- IMMUTRI (NCT01041469)
- Where
- 2 sites in France
- Volunteers
- 72 people
- Sponsor
- Institut Jerome Lejeune
Paraneoplastic Neurological Syndrome, Autoimmune Encephalitis
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Detection of autoantibodies targeting neuronal surface or intracellular antigens is a keystone for the diagnosis and the treatment of auto-immune encephalitis and paraneoplastic neurological syndromes.
- Trial name
- IFINEURO (NCT05783947)
- Testing
- Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera
- Where
- 2 sites in France
- Volunteers
- 34 people
- Sponsor
- Hospices Civils de Lyon
B-cell Acute Lymphoblastic Leukemia
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main method potentially curing adult B-ALL, but the high treatment-related mortality (NRM) affects overall survival (OS).
- Trial name
- NCT06507514
- Testing
- blinatumomab and auto-HSCT "sandwich " strategy
- Where
- China
- Volunteers
- 4 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Type 1 Diabetes
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
Type 1 diabetes (T1D) is caused by the destruction of insulin-producing cells by effector T cells (Teffs), due to a deficiency of regulatory T cells (Tregs).
- Trial name
- DF-IL2-REP (NCT05153070)
- Testing
- Cyclosporin, ILT101
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Warm Autoimmune Hemolytic Anemia
Rituximab in Auto-Immune Hemolytic Anemia
The hypothesis based on retrospective data is that, the rate of overall response-rate (PR + CR) at 1 year will be much higher in the rituximab arm (80%) than in the placebo arm (20%).Thirty four patients (17 in each arm) will be…
- Trial name
- RAHIA (NCT01181154)
- Testing
- rituximab (Mabthera®)
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 1 Diabetes Mellitus (T1DM)
Digital Tracking With Auto Data Reporting
Type 1 diabetes mellitus is a chronic pathology and represents a constant challenge for children and adolescents with diabetes and their families.
- Trial name
- NCT06707155
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Persei Vivarium
Diabetes Mellitus, Type 1
The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients
The goal of this research is to see if pancreatic polypeptide (PP), a hormone that is naturally produced by the pancreas and that works to control the amount of glucose that the liver makes, will reduce the amount of insulin…
- Trial name
- NCT00791076
- Testing
- Pancreatic Polypeptide (PP)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University
Lymphoma, Multiple Myeloma
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell…
- Trial name
- NCT03383055
- Testing
- CMV-MVA Triplex Vaccine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Juvenile Idiopathic Arthritis
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…
- Trial name
- NCT02396212
- Testing
- Canakinumab
- Where
- 7 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
CAR, B Cell Lymphoma
ThisCART19A for B-NHL Relapsed After Auto-CAR T
This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma.
- Conditions
- CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT05691153
- Testing
- ThisCART19A with Dose Level 1, ThisCART19A with Dose Level 2
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Type 1 Diabetes
Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes
Type 1diabetes (T1D) is caused by autoimmune destruction of the pancreatic islet ß-cells, leading to an absolute deficiency in insulin.
- Trial name
- DIABIL-2 (NCT02411253)
- Testing
- rhIL-2
- Where
- 34 sites in Belgium, France and 4 more
- Volunteers
- 141 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
- Trial name
- NCT03125642
- Testing
- Etoposide, BCNU, AraC
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
The goal of this clinical research study is to learn if curcumin can reduce the symptoms reported by patients with multiple myeloma (MM) who receive treatment with lenalidomide.
- Trial name
- NCT01269203
- Testing
- Curcumin
- Sponsor
- M.D. Anderson Cancer Center
Celiac Disease in Children, Diabetes Mellitus, Type I
Auto-antibody Dosage From Blood Spots for Diagnosis of Type 1 Diabetes and Celiace Disease
Early diagnosis of type 1 diabetes and celiac disease is very useful, allows early therapy and prevents deaths from the onset of diabetic ketoacidosis.
- Conditions
- Celiac Disease in Children, Diabetes Mellitus, Type I, Screening
- Trial name
- CELDI (NCT06849622)
- Testing
- Test on blood sample, Test on dried blood sample
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Meyer Children's Hospital IRCCS
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade
Tandem Auto-Allo Transplant for Lymphoma
Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in…
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT01181271
- Testing
- Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
The goal of this clinical trial is to learn if high-dose Melphalan HCl for Injection works to treat multiple myeloma. It will also learn about the safety of high dose Melphalan HCl for Injection.
- Trial name
- NCT06425276
- Testing
- Melphalan Hydrochloride for Injection
- Where
- China
- Volunteers
- 67 people
- Sponsor
- CASI Pharmaceuticals (China) Co., Ltd.
Familial Cold Autoinflammatory Syndrome
Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.
- Trial name
- DFV890-FCAS (NCT04868968)
- Testing
- DFV890
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant approach in newly diagnose myeloma patients younger than 65 years
- Trial name
- NCT00702247
- Testing
- Hematopoietic Stem Cell Transplantation
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista